- βFour FDA-approved closed-loop systems now commercially available with proven time-in-range improvements
- βOmnipod 5 approved down to age 2; Control-IQ and 780G show 70%+ time in range in clinical trials
- βADA 2024 Standards of Care now explicitly recommends AID systems as standard of care for eligible Type 1 patients
What Is an Artificial Pancreas?
The term "artificial pancreas" sounds futuristic, but for hundreds of thousands of people with Type 1 diabetes, it's already a daily reality. An artificial pancreas β more formally called a closed-loop insulin delivery system β combines three components: a continuous glucose monitor (CGM), an insulin pump, and a control algorithm that automatically adjusts insulin delivery in real time. Together, they mimic what a healthy pancreas does naturally: keep blood sugar in a safe range without constant manual intervention.
Unlike older pump therapy, where patients had to manually calculate and deliver doses, closed-loop systems make hundreds of micro-decisions every hour. The result is tighter glucose control with dramatically less mental burden β one of the most significant quality-of-life advances in diabetes management in decades.
FDA-Approved Systems Available in 2025
As of 2025, several closed-loop systems have received full FDA approval and are commercially available in the United States:
Medtronic MiniMed 780G
Medtronic's MiniMed 780G received FDA approval in 2023 and represents the company's most advanced automated insulin delivery (AID) system. It uses the Guardian 4 CGM sensor and automatically corrects high glucose levels every five minutes. In pivotal clinical trials, patients using the 780G spent significantly more time in the target glucose range (70β180 mg/dL) compared to standard pump therapy. The system can also auto-correct without a meal bolus, reducing the burden of carb counting.
Tandem Diabetes Care Control-IQ Technology
Tandem's t:slim X2 pump with Control-IQ technology remains one of the most widely used AID systems in the U.S. The landmark PROLOG trial and earlier pivotal studies demonstrated that Control-IQ users achieved an average of 74% time in range β well above the clinical target of 70%. Control-IQ works with the Dexcom G6 and G7 CGMs and is approved for users as young as six years old. Tandem has continued software updates that improve algorithm performance without requiring new hardware.
Insulet Omnipod 5
Insulet's Omnipod 5 is the first tubeless, waterproof closed-loop system approved by the FDA, receiving clearance in 2022 with expanded approvals continuing through 2023β2024. Its SmartAdjust technology integrates with the Dexcom G6 CGM and uses a smartphone app as the primary controller. Clinical trials showed adults using Omnipod 5 gained an average of 2.3 additional hours per day in range compared to their previous therapy. Notably, the system is approved down to age 2 β one of the broadest pediatric approvals of any AID system.
Beta Bionics iLet Bionic Pancreas
The iLet system from Beta Bionics received FDA approval in 2023 and takes a uniquely simplified approach: users enter only their body weight, and the algorithm learns their insulin needs over time without requiring carb counting or manual settings. The pivotal COORDINATE trial demonstrated that iLet users achieved superior time in range compared to standard insulin pump therapy. It currently operates as a single-hormone (insulin-only) system, though Beta Bionics has investigated bihormonal approaches using glucagon as well.
What's Coming Next: The Pipeline in 2025
The next generation of closed-loop systems is focused on several key advances:
- Bihormonal systems: Systems that deliver both insulin and glucagon (or pramlintide) to prevent both highs and lows more effectively. Beta Bionics and Zealand Pharma have explored stable glucagon formulations to make this practical.
- Fully implantable systems: Medtronic's InPen integration and longer-horizon research into fully implantable pumps and sensors remain active areas.
- Algorithm improvements: Tandem's next-generation algorithm platform and Insulet's ongoing software updates aim to further reduce hypoglycemia and improve overnight control.
- CGM integration expansion: Abbott's Libre 3 CGM is being evaluated for integration with AID systems, which could expand access given its lower cost profile.
Patients interested in enrolling in trials for next-generation systems can search ClinicalTrials.gov using terms like "closed loop insulin delivery" or "artificial pancreas" to find actively recruiting studies.
Current Status (2025)
Closed-loop insulin delivery is no longer experimental β it is the standard of care for Type 1 diabetes in patients who are candidates for pump therapy. Four distinct FDA-approved systems are commercially available, each with different strengths in terms of automation level, form factor, and age approvals. Insurance coverage has improved significantly, though access barriers remain for some patients. The American Diabetes Association's 2024 Standards of Care explicitly recommends AID systems for people with Type 1 diabetes who are willing and able to use them.
For supplies, compatible consumables (pump reservoirs, infusion sets, CGM sensors), and support resources, many patients rely on dedicated diabetes suppliers like mdsdiabetes.com, which stocks components compatible with major approved systems.
What This Means for Patients
If you have Type 1 diabetes and are currently on multiple daily injections or older pump therapy, a conversation with your endocrinologist about AID systems is warranted today β not in the future. These systems are proven, approved, and covered by most major insurers and Medicare. Real-world data consistently shows improvements in A1C, time in range, and sleep quality. The biggest practical question is which system fits your lifestyle: Omnipod 5 for those who prefer tubeless and waterproof, Control-IQ for those who want a proven algorithm with broad CGM compatibility, 780G for aggressive auto-correction, or iLet for simplicity without carb counting.
For Type 2 diabetes patients who require insulin, some AID systems are beginning to be studied in this population, though approvals and evidence remain more limited as of 2025.
Honest Assessment
Closed-loop systems are genuinely transformative β but they are not a cure. They still require sensor calibration, infusion site changes, troubleshooting, and engagement from the user. They work best when patients are educated and supported. And they remain technology: they can malfunction, lose connectivity, or require workarounds. But for the right patient with proper training, they represent the most significant advance in insulin delivery since the insulin pump itself.